# Safety and Efficacy of Low-dose hEparinization in Cerebral Angiography sTudy

Study · id `cardio:ct-nct06365398` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06365398](<https://clinicaltrials.gov/study/NCT06365398>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06365398

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT06365398. Randomized; triple masking; primary purpose treatment. Start 2018-01-01 (actual); primary completion 2021-06-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT06365398, source copy `cardio:ctgov-nct06365398-2024-04-15`, retrieved 2026-10-26)
- Started: 2018-01-01 (actual) (ClinicalTrials.gov record NCT06365398, source copy `cardio:ctgov-nct06365398-2024-04-15`, retrieved 2026-10-26)
- Primary completion: 2021-06-01 (actual) (ClinicalTrials.gov record NCT06365398, source copy `cardio:ctgov-nct06365398-2024-04-15`, retrieved 2026-10-26)
- Completion: 2022-01-01 (actual) (ClinicalTrials.gov record NCT06365398, source copy `cardio:ctgov-nct06365398-2024-04-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06365398, source copy `cardio:ctgov-nct06365398-2024-04-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06365398-2024-04-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Low-dose hEparinization in Cerebral Angiography sTudy
- Acronym: SELECT
- Condition: Cerebral Angiography
- Condition: Heparinization
- Intervention (Drug): Heparin
- Intervention (Drug): Heparin Sodium Injection
- Intervention (Other): No heparinization
- Lead sponsor: Xuanwu Hospital, Beijing
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Heparin (`cardio:heparin`)
- Registry intervention is a member of this class by a sourced record link: Heparins and low-molecular-weight heparins (`cardio:heparins-and-low-molecular-weight-heparins`)
- Registry intervention is a member of this class by a sourced record link: Anticoagulants (`cardio:anticoagulants`)
- Registry lists this organization as the lead sponsor: Xuanwu Hospital, Beijing (`cardio:org-xuanwu-hospital-beijing`)

## Provenance

Content hash: 2ea75a131b562d1a3798618116fe358dc4504a7c4c55a9f7443788d28bc9840d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
